Apple wins patent lawsuit (and $250) from Masimo — but it won’t affect Apple Watch’s MIA blood oxygen feature
A jury has ruled that Apple did not infringe on Masimo's patents related to pulse oximetry technology. The case was closely watched as it could have had implications for the future of Apple's health tracking features.Masimo, a medical device company, had accused Apple of infringing on its patents for pulse oximetry technology, which is used to measure blood oxygen levels. The technology is used in a variety of medical devices, including Apple's Apple Watch.The jury found that Apple did not infringe on Masimo's patents. The jury also awarded Masimo $250 in damages.The verdict is a victory for Apple, as it means that the company can continue to develop and sell its health tracking features without fear of being sued by Masimo.However, the verdict is unlikely to have any impact on the Apple Watch's MIA blood oxygen feature. Apple has not yet released a blood oxygen sensor for the Apple Watch, and it is unclear when or if the company will do so.The verdict is a reminder that the patent system can be a complex and unpredictable process. Even when a company wins a patent lawsuit, it does not always mean that the company will be able to commercialize the technology.In this case, Apple was able to win the patent lawsuit, but it is still unclear whether the company will be able to bring a blood oxygen sensor to market.